urinary catheter (P = 0.005) and in cases with previous admittance to hospital compared to cases without previous admittance to hospital (P = 0.008).
Conclusions:
This study found an exceptional high rate of antibiotic resistance, and a low rate of effective empirical antibiotic treatment. Guidelines on antibiotic treatment are needed, and for empirical treatment of nosocomial UTI an increased use of nitrofurantoin and amikacin is recommended, rather than cephalosporins and fluoroquinolones.
BACKGROUND Antibiotic resistance
Antibiotic resistance (ABR) is a normal evolutionary process. In environments where antibiotics are abundant and thus constitute an important selection pressure, mutations that entail resistance provides a competitive advantage to the microbes carrying it and are therefore favoured in the natural selection. The vast use of antibiotics in hospitals and the community -as well as in agriculture -over the last decades have accelerated this process to a point where ABR have emerged as a global health problem. Widespread resistance to antibiotics is not only creating difficult-to-treat infections associated with high mortality, but also threatening major progresses in modern medicine like major surgery and cancer chemotherapy, as well as having social and economic impact [1, 2] . Bacteria with resistance to broad-spectrum antibiotics are increasing, and with the emergence of multidrug-resistant bacteria there is an increasing fear that we are heading towards a post-antibiotic era [2] [3] [4] .
Resistance to antibiotics are now found all over the world, and have even been found in the Arctic -a region without selection pressure for resistance development [5] . Resistance is spread between bacteria, humans and regions by means of transmission of resistance genes between bacteria (e.g. plasmids and transposons), poor sanitation and hygiene in hospitals and communities, and global travel, trade and migration.
Since the turn of the millennium, bacteria of the family Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL) -enzymes providing resistance to almost all β-lactam antibiotics (like penicillin and cephalosporins) except carbapenems -have emerged as an important cause of infections, including urinary tract infections (UTI). They have since spread to all over the world and are often associated with multi-drug resistance including resistance to co-trimoxazole, aminoglycosides and ciprofloxacin -important antibiotics in the (empirical) treatment of UTI [6] . Since a few years back, we also see an alarmingly rapid world-wide dissemination of resistance against carbapenems [7] . One example is the New Delhi metallo-β-lactamase 1 (NDM-1) gene, first identified in Sweden 2008 in a urine culture from a patient previously hospitalized in New Delhi [8] . Within a few years, the gene had spread to large parts of the world [9] [10] [11] . The NDM-1 gene is exhibiting several worrisome characteristics like being associated with plasmids carrying high number of genes mediating resistance to virtually all antibiotics but tigecycline, colistin and fosfomycin, as well as being found in many unrelated species of bacteria including Klebsiella pneumoniae (a common nosocomial pathogen) and Escherichia coli (the main community-acquired human pathogen) [9, 12] , also the two main pathogens of UTI [13] .
Selection of resistance genes and spread of bacteria with ABR is mainly a local process, with practices in individual hospitals and communities playing a critical role [2] . Resistance genes may be transferred to bacterial spices capable of causing other kinds of infections than the original one. Successful genes may then be further selected and transferred to new hosts, and in that process being amplified and established as important resistance genes, especially if the selection pressure of antibiotics continues. They can then spread through different kinds of bacteria nearly everywhere through the world's interconnecting commensal, environmental, and pathogenic bacterial populations. As an example, resistance to sulfonamides has been found throughout the world encoded by only 2 resistance genes [14] .
The combination of highly susceptible patients, intensive and prolonged antibiotic use and cross-infections make hospitals a hotspot for both evolution and spread of ABR. Emergence of resistant strains in hospitals occurs when a patient infected with a resistant bacteria is transferred to the hospital from another facility, by patient-to-patient transfer, through selection caused by antibiotic use, and by transfer of resistance genes. Overcrowding, limited capacity and poor sanitation make the situation worse in many low and middle-income countries (LMICs). Healthcare-associated infections are a problem worldwide, adding not only to the burden of both infections and ABR but also constituting a major threat to patients' safety. A review [15] found the pooled prevalence of overall healthcare-associated infection in LMICs to be 15.5 per 100 patients, twice as much as in Europe (7.1 per 100 patients) [16] .
Gram-negative bacteria represented the most common isolates in nosocomial infections.
The rate of resistance varies widely between bacteria, class of antibiotic, countries, patient categories and healthcare facilities. Different levels of resistance between and within countries might be explained by differences in consumption [17] . Worldwide the antibiotic consumption is increasing, including carbapenems [2] . The use of non-prescription antibiotics are common in many parts of the world and outside of northern Europe and North America non-prescription use account for 19 -100 % of antimicrobial use [18] . Increasing nonprescription use of antibiotics has been associated with clinically important ABR, including high levels of resistance in E. coli in urinary cultures [18] [19] [20] . In countries with limited and/or poor access to healthcare, a ban on over-the-counter antibiotics might impede vital access to antibiotics. Especially in LMICs this provides a dilemma on how to ensure access to antibiotics without excessive or inappropriate use. The access and excess dilemma is however not restricted to non-prescription use (or to the LMICs) since prescribed antibiotic could be unnecessary or suboptimal, or patients in need are not given treatment due to therapeutic, financial and structural barriers. As an example, less than a third of children in LMICs with suspected pneumonia receive potentially life-saving treatment with antibiotics at the same time as antibiotics are too often prescribed for diarrhoea instead oral rehydration salts and zinc [21, 22] .
Both the prevalence of ABR around the world, and the burden of it, is inadequately studied [1, 2] . Most studies are carried out in a hospital setting, often with cultures from severely ill patients where first-line treatment have failed. Community-acquired infections and infections treated in out-patient-care are underrepresented. This may exaggerate the rates of ABR and further drive the use of broad-spectrum antibiotics, which in turn may further accelerate the evolution and spread of resistance [1] . The burden of ABR is thought to the result of longer duration of illness and higher mortality, increasing costs of treatment and inability to perform procedures that require antibiotics to prevent infections [2] . An often cited study from 2007 [23] estimated that each year about 25 000 patients in the European Union, Iceland and Norway die from an infection with resistant bacteria, and that ABR result in extra healthcare costs and productivity losses of at least EUR 1.5 billion each year. Although poorly studied, the higher prevalence of infectious diseases and restricted access to healthcare and secondline antibiotics in LMICs, it is estimated that the burden probably is higher than in highincome countries, and since two thirds of childhood mortality is associated with infections, children are probably more affected than adults [2, 24] . Adding onto the already complex issue of ABR, the situation in many LMICs is often further aggravated by poverty, which leads to poor sanitation, hunger and malnutrition, inadequate access to drugs, poor and inadequate health care systems, civil conflicts and bad governance [25] . Also, the problem of resistance might not be adequately recognised by most stakeholders as there are higher priorities to address such as provision of basic health care or sanitation.
As have been pointed out above, we are now in a situation where ABR is found worldwide, and in many places constitute an important medical problem. There is no single, easy solution to this problem, but rather a need for a multitude of actions and strategies. Effective infectioncontrol practices and good hygiene are the foundation in controlling the spread of antimicrobial resistance in healthcare settings. In communities, reduction in infections and decreased colonisation and transfer of resistant bacteria and resistance genes can be achieved through reduction of poverty, improved sanitation and access to clean water [2] . Improvement in rational use of antibiotics through so called antibiotic stewardship programs with education, treatment guidelines, restricted availability to certain antibiotics, surveillance of ABR and antibiotic usage, and post prescription audit and feedback of antibiotic use, can decrease the emergence of antimicrobial resistance and reduce colonization or infection with resistant bacteria [26, 27] . As an example, a study [28] done in a university-affiliated hospital found that a new antibiotic guideline that reduced the use of cephalosporins by 80 % led to a 44 % hospital-wide decrease in ESBL-producing Klebsiella isolates within 1 year. Antibiotic stewardship programs should also be expanded to LMICs, primary care settings and the community, and adjusted to local conditions. Where prescriptions of antibiotics are a source of revenue -either for individuals or institutions such as hospitals -efforts should be made to separate prescription and dispensing [2] . New antibiotics needs to be developed. Since the 1970:s only two new classes of antibiotics have reached the market, and the number of new analogues are decreasing. At the moment though, the pipeline for new antibiotics is almost dry [2] . However, resistance will eventually arise to all antibiotics, so new antibiotics needs to be used with caution and be paired with effective stewardship programmes. To avoid pharmaceutical companies maximising profits on new antibiotics by selling large quantities, delinkage of revenues and the use of the product is needed and instead new models of income needs to be developed, as well as models permitting global access at affordable prices [2, 29] .
In the meantime -while we wait for new antibiotics to appear -new approaches are needed to address the problem. Studied today are: anti-virulence approaches, phage therapy, therapeutic antibodies, drugs based on antimicrobial peptides, potentiators of traditional antibiotics (like the β-lactamase inhibitors already in clinical use) and efflux pump inhibitors, and antibacterial biomaterials [30] .
Antibiotic resistance and its consequences a serious threat to public health akin to that of anthropogenic global warming, and calls for concerted global action. We need a worldwide coalition of governments with a strong representation from LMICs, WHO and other UN agencies, other international bodies, science academies, development aid agencies, civil society organisations and pharmaceutical companies to develop a global plan to tackle the antibiotic crisis.
Urinary tract infections
Urinary tract infections are among the most common bacterial infections in humans, both as community-acquired and healthcare-associated infections. It is the most common nonsurgical nosocomial infection in postoperative patients and the second most common healthcareassociated infection [15, 31] . As the second most common reason for empirical antibiotic treatment, UTI is a major driver of antibiotic usage globally [32] . It have a wide spectrum of severity -and even though a usually benign infection -the occurrence of a UTI in a surgical patient is associated with a threefold increase in death during hospitalization [33] . Hence, the prevention and treatment of UTI is therefore of great concern for the survival and wellbeing of the individual surgical patient.
Bacteriuria -the presence of bacteria in the urine -can be subdivided into the following categories and definitions [13, 32] :
 Asymptomatic bacteriuria (ABU) -bacteriuria in the absence of symptoms. Should generally not be treated.
 Symptomatic bacteriuria -bacteriuria in the presence of typical symptoms for UTI.
 Lower UTI -the infection is localized in the lower urinary tracts, i.e. the bladder and urethra. Fever is uncommon and the general condition of the patient is usually unaffected.
 Upper UTI -the infection is localized to the upper urinary tracts, also called pyelonephritis; a much more severe condition than lower UTI, and frequently causes sepsis (urosepsis).
 Complicated UTI -upper UTI and/or UTI in individuals with predisposing factors such as structural and functional abnormalities in the urinary tracts, metabolic disorders or impaired immunity. UTI in children and men are often considered to be complicated UTI, and are more often caused by multi-resistant organisms.
E. coli is by far the most common pathogen, often accounting for more than 80 % in uncomplicated UTI, although most studies are done in high-or middle-income countries.
Other pathogens (so-called secondary pathogens such as Klebsiella spp, Enterobacter, Proteus spp) and are usually found in patients with complicated UTI. Generally, these pathogens have a decreased susceptibility to many antibiotics [13] .
Predisposing factors for UTI include structural and functional abnormalities, foreign bodies, metabolic abnormalities, impaired immunity and urological surgery and instrumentation [32] .
Indwelling catheter use is a known risk factor for UTI, with duration of catheterization as the single most important risk factor [32] .The bacteria is often of several different species, often multi-resistant [13] . Catheter-associated UTI make up a large proportion (approximately 30 -40 %) of the healthcare-associated infections, and as many as 10 % of patients in a urological wards have healthcare-associated complicated infections [32] . coli and Klebsiella spp resistant to fluoroquinolones [36, 38] . These findings are in line with figures from WHO, however they reported a resistance rate of E. coli to fluoroquinolones of 64.3 % [1] .
AIMS
This is a hospital-based retrospective descriptive study in two parts that aims to study:
1) Pathogens and antibiotic susceptibility among patients with presumed complicated UTI at a surgical clinic in a tertiary care hospital in Nepal.
2) The use of antibiotics, rationality of antibiotic treatment and surgical risk factors.
METHODS
The study was performed at Patan Hospital, a tertiary care hospital located in Patan (adjacent to Kathmandu), Nepal. It is one of the largest hospitals in the country, treating 320 000 For Part 2, all cultures with a growth of more than 100 000 CFU/ml and from a patient with a six digit hospital number (which means that the medical chart were kept in the hospital's archive) during the study period where then selected for review of their medical chart. With this criteria 70 cases were found (a case was defined as an independent illness episode), and of these 50 cases (71 %) of 48 unique patients (two patients occurring two times) were found and retrieved in the hospital's archive; representing 37 % of cultures with significant growth and 6 % of total cultures. In accordance with other studies from Nepal [36] [37] [38] , and local hospital definition of UTI, over 100 000 CFU/ml were considered significant growth and hence this definition is used in this part of the study.
The surgical ward at the hospital provided care for in-patients requiring 24-hour medical attention, while the surgical reference clinic treated out-patients coming to appointments with 
Patients in Part 2
The number of female cases was 22, and male cases 28. Distribution of age and sex is presented in figure 2 below. No interviews were done with the patients, and all patient data are derived from medical charts. From the surgical ward came 20 cases (40 %) and from the surgical reference clinic 30 cases (60 %). The urine samples were inoculated onto agar plates (blood agar and MacConkey agar) using calibrated loop. After incubation the plates were examined for bacterial growth and quantified. For positive cultures, bacterial identification was done using morphological characteristics, Gram staining and various biochemical tests. The sensitivity testing was done using the Kirby-Bauer disk diffusion susceptibility test.
Statistics
All documentation in the hospital were handwritten and in English. 
RESULTS

Part 1
Antibiotic susceptibility
In Part 1, 136 cultures (18 %) with nine different species of bacteria were found (figure 3).
The most common pathogen was Escherichia coli (E. coli, 74 %), the second most common was Klebsiella spp (12 %) . Of all cultures, 110 (14 % of total) had more than 100 000 CFU/ml, 75 % of those were E. coli (69 % from the surgical ward, 77 % from the surgical reference clinic [no statistical significance]). Worth noting is that no culture of Salmonella spp were found, despite being a common cause of blood stream infections in Nepal [41, 42] . The mean susceptibility of all the cultures combined is presented in figure 4 . One culture each of E. coli and Acinetobacter spp have been omitted since susceptibility tests were not performed on these, giving a total of 134 cultures. Cultures with a high degree of resistance to common antibiotics were tested for further antibiotics (table 1) . It is however important to notice that these antibiotics were only tested on a small number of cultures. The susceptibility of E. coli to common antibiotics is shown in figure 5 . For one culture of E.
Susceptibility of all positive cultures
coli no susceptibility test was done, and this culture have been omitted from further analyses.
Hence, the susceptibility analyses are based on 100 cultures of E. coli. Table 2 shows the extended susceptibility testing. Of these, 10 were tested for imipenem (a carbapenem), which gave four resistant, one intermediate and five sensitive cultures. Of the five resistant or intermediate cultures, four were E. coli and one Klebsiella spp. Of these, four were tested for colistin and three for tigecykline -all of these were found to be sensitive.
Part 2
Patient characteristics
The bacteria found in Part 2 are presented in table 5. There were 27 (54 %) cases were signs or symptoms of UTI were recorded. Information about clinical signs or clinical evaluation for the other 46 % of the patients was not mentioned in the medical records. Twenty cases (40 %) had an indwelling urinary catheter at the time the urine sample was taken, 23 % of female cases and 54 % of male cases. Cases with indwelling urinary catheter had a statistically significant increased likelihood of a non-E. coli pathogen (figure 9). No statistically significant differences in pathogens were seen between female and male cases, or in cases younger or older than 50 years. Nineteen cases (38 %) had been treated for UTI in the preceding 12 month, seven (37 %) of these cases more than once (two cases lacked record of number of previous UTI:s). Thirteen cases (26 %) had benign enlargement of prostate, five cases (10 %) had nephrolithiasis and one case (2 %) a bladder stone when the urine sample was taken.
Culture result
Number of cases
Acinetobacter spp 1 (2 %) Citrobacter freundii 1 (2 %) E. coli 36 (72 %) Enterobacter 2 (4 %) Klebsiella spp 5 (10 %) Morganella morganii 1 (2 %) Proteus spp 2 (4 %) Pseudomonas spp 2 (4 %)
Previously prescribed antibiotics Number of occasions Amikacin
The primary diagnosis is displayed in table 7, the associated pathogens in figure 10 
E. coli and non-E. coli pathogens in the main primary diagnoses (hence the different numbers compared to table 7). The differences between the pathogen groups were statistically significant for surgical-and urological condition vs infection and internal medicine condition (P = 0.001).
Secondary diagnosis
Treatment
To evaluate the antibiotic treatment of UTI and the rationality of the treatment proved difficult, mainly due to that many patients were treated for other conditions and infections than UTI, and to receive clarity on the indication(s) for each antibiotic was most often not possible. Also, only the date of the first dose was noted, and duration of each antibiotic was not included in the study. This made it difficult to determine if patients receiving more than one antibiotic were treated with multiple antibiotics simultaneously or if the antibiotic treatment was changed. Also, only new kinds of antibiotics to the patient were noted.
In total the patients were prescribed 87 antibiotics (table 9) . In seven cases (14 %) there was no record of any antibiotic treatment at all. However: in 13 cases (26 %) three or more (with a maximum of six) different antibiotics were given. The combinations used as first-line and second-line treatment is shown in table 10 and table   11 , and the susceptibility to the antibiotics in first-line treatment in figure 11 . First-line treatment were defined as antibiotics prescribed within five days before and seven days after culture sample was taken, second-line treatment as a new prescription of antibiotic after three days. Note however that "sensitive" only means that at least one antibiotic prescribed were effective against the bacteria in the culture, and it is not possible to say for how long time that antibiotic was used. It is worth noting however, that of the cases receiving antibiotic treatment, only 55 % of cases got at least one antibiotic to which the bacteria was sensitive.
All antibiotics prescribed
No statistical significant difference in treatment effectiveness (measured as resistant, not effective, and not tested vs sensitive) between cases in the surgical ward and cases in the surgical reference clinic could be seen. Out of the 42 cases in table 10 (first-line treatment), 7 cases (17 %), received second-line treatment, which has been interpreted as treatment failure.
First-line treatment
Antibiotic susceptibility in various risk factors
Finally, the antibiotic susceptibility to ciprofloxacin and cefotaxime were compared in different sub-groups in the study. Ciprofloxacin and cefotaxime were regarded as most relevant antibiotics to compare since they were the most common empiric treatment for UTI (amikacin excluded due to low overall resistance rate). Intermediate cultures have been considered resistant in the statistical calculations.
In Part 1, a statistical significant higher resistant to both ciprofloxacin and cefotaxime were found in cultures from the surgical ward compared to cultures from the surgical reference clinic ( figure 12 ). In Part 2, statistical significant differences were found for resistance to ciprofloxacin (but not to cefotaxime) between cases with or without indwelling urinary catheter (figure 13), and in cases with previous admittance to hospital (figure 14) . No statistically significant increase in resistance to either ciprofloxacin or cefotaxime was found in cases with previous surgery of the urinary tract, urological condition as primary diagnosis, previous antibiotic treatment, and previous UTI. 
DISCUSSION
The main finding in this study were the exceptionally high levels of resistance to virtually all clinically relevant antibiotics. Highest degrees of resistance were found in fluoroquinolones, the most commonly prescribed antibiotics in this study. Amikacin and nitrofurantoin proved to be the antibiotics with the most favourable resistance rates (nitrofurantoin only for E. coli).
Although carbapenems were tested in a too limited number of cultures to draw reliable conclusions, 50 % were resistant. In the light of that previous studies in Nepal have found no resistance to carbapenems, this raises a warning that resistance to carbapenems might be on the rise in Nepal. Throughout monitoring of local antibiotic resistance is of paramount importance to tackle this problem.
The other main finding was the ineffectiveness of the first line treatments. Only 55 % of cases treated with antibiotics were treated with at least one antibiotic that were effective against the bacteria. In many cases, the effective antibiotics were only aminoglycosides. The high rates of Looking into the differences in susceptibility to ciprofloxacin and cefotaxime for a number of known risk factors for complicated UTI and ABR, significantly higher resistance were found in cultures from the surgical ward compared to the surgical reference clinic. In cases with indwelling urinary catheter and in cases with previous admittance to hospital, a statistically significant higher resistance to ciprofloxacin were found. This could probably be explained by a higher risk of (previously) being colonized by a strain of fluoroquinolone-resistant bacteria in an environment with a high presence of resistant bacteria. The lack of statistical significant differences between the other groups could be explained by the small number of cases in each group, or confounding factors.
Part 1
Although high levels of ABR were found for all pathogens to all antibiotics, especially worrying are the high rates of resistance against fluoroquinolones, which besides being the most used antibiotics in this study, also are a per oral (p.o.) antibiotic meaning it can be used in an out-patient settings. Co-trimoxazole -another p.o. drug -had in E. coli isolates a slightly lower resistance rate than fluoroquinolones. Nitrofurantoin (p.o), had a relatively low resistance rate in E. coli (24 % resistant, 13 % intermediate), but high for both Klebsiella spp and non-E. coli (over 80 % resistant). Third generation cephalosporins (cefotaxime/ceftriaxone, both intravenously [i.v.] administrated) had lower resistance rates than fluoroquinolones, although still high, and a pronounced difference between E. coli, Klebsiella spp and non-E. coli were noted. No testing for ESBL-producing bacteria were conducted, but a study from Kathmandu in 2013 found 13.51 % of E. coli and 16.55 % of Klebsiella pneumoniae to be ESBL positive [37] . Amikacin (i.v.) had the lowest rates of resistance among all the commonly used antibiotics, and noticeably lower than gentamycin.
No major differences were seen between E. coli, Klebsiella spp and non-E.coli.
Carbapenems, piperacillin-tazobactam, colistin and tigecycline were only tested on a small number of isolates, and hence reliable conclusions cannot be made. However, colistin and tigecyclin seem to have low rates of resistance. On the other hand, the resistance to carbapenems appear to be around 50 %, a finding contradictory to other studies where no resistance to carbapenems have been found [1, 37] . This indicates a possible rise in resistance to carbapenems, and once again stresses the importance of ABR monitoring. No use of carbapenems, piperacillin-tazobactam, colistin or tigecycline was found in the studied medical records. This raises the question on the origin of the resistance to carbapenems found in this study. A study from New Delhi in 2011 found NDM-1-producing bacteria in drinking water and seepage samples, indicating a possibility of acquiring resistant bacteria outside of healthcare facilities, and this might be a possible origin, apart from other departments or health-care facilities [44] .
Compared to previous studies from Nepal [36] [37] [38] and data from WHO [1] , the susceptibility patterns were similar, although resistance rates were often higher in this study. In these studies the resistance of E. coli to fluoroquinolones were 35.9 % -64.3 %, and to third generation cephalosporins 19.2 % -37.9 %. In Klebsiella spp the resistance to fluoroquinolones were 4.3 % -16.7 %, and to third generation cephalosporins 3.2 % -48.3 %.
However, different cephalosporins (ceftazidime, cefotaxime and ceftriaxone) were used in the different studies, making comparisons of resistance to cephalosporins somewhat uncertain.
Nitrofurantoin had a comparable resistance rate in [38] , and a lower (7.9 %) in [36] . Amikacin were the antibiotic with highest susceptibility in all three studies [36] [37] [38] .
The findings in this study of high levels of ABR, especially considered together with the widespread use of fluoroquinolones and the low success rate of first line treatments, a change in empirical treatment of UTI in surgical patients at Patan Hospital could be advised.
Fluoroquinolones and third generation cephalosporins should be avoided, both due to low probability of treatment success, and also to slow down even further increase in resistance. A high resistance to these antibiotics might increase the use of carbapenems, and with it the risk of increased resistance to them. As a p.o. treatment, nitrofurantoin could be used as a first line treatment in patients (including men) with uncomplicated, lower UTI without fever and with high probability of E. coli [13, 36, 37, 45] . Considering that the resistance to co-trimoxazole were similar to that of fluoroquinolones and third generation cephalosporins in E. coli isolates, it too could be considered as an alternative. When an i.v. drug is needed, amikacin seem to be the best alternative, with good effect on upper UTI and septicaemia and high susceptibility among all major pathogens [36, 37] . Nitrofurantoin and amikacin are also effective in cases of ESBL-producing pathogens [37, 45] .
Being a highly selected group of patients with a high prevalence of risk factors for increased ABR, conclusions and extrapolations to the general patient population should be done with cautions. However, a general shift in treatment of UTI towards nitrofurantoin and amikacin could be advised. The importance of culture and antibiotic susceptibility testing cannot be overstated. Since Patan Hospital accepts patients from all over the country, a widespread ABR in the hospital also implies the risk of people from remote areas acquiring resistant bacteria, and then may act as carriers of drug resistant pathogens back to their native areas.
In this study, a lesser percentages of cultures were positive compared to previous studies from Nepal. A study from Kathmandu had 30.8 % positive cultures in a hospital setting with a mixed study population of in-and out-patients [36] , whereas a study from Pokhara found 71.1 % positive cultures in hospitalized patients only [38] . It was in this study not possible to know if the patient was already on any kind of antibiotic, and whether this could be a contributing factor to the relatively low percentage of positive cultures. However, while there could be a number of other reasons contributing to the different figures, it shows the importance of culture in addition to patient history and clinical examination to confirm the diagnosis of UTI.
The dominating bacteria found E. coli. In cultures with more than 100 000 CFU/ml E. coli made up 75 % of positive cultures, and in cultures from the surgical ward only the number were 69 %. This can be compared to 81.3 % in [36] , and 59.4 % in [38] . In a North American and European material, E. coli made up 47 % and 36 % of positive cultures among hospitalized patients, respectively [46] . Among out-patients, E. coli often make up over 80 % of UTI [13] . This corresponds well with the conception that the proportion of complicated UTI caused by non-E. coli pathogens is higher in a hospital setting. Still, the proportion of E.
coli in hospitalized patients in this study was relatively high.
Part 2
The success rate of the first line treatment reflects the high resistance rate. Only 55 % of cases treated with antibiotics were treated with at least one antibiotic that were effective against the bacteria. In many cases, the only effective antibiotic were an aminoglycoside, and since this is an i.v. drug and hence only can be administrated to admitted patients, the real effectiveness of the antibiotic treatment once the patient have been discharged is hard to determine and probably even somewhat lower than suggested. 17 % of cases had treatment failure and The most common antibiotics used in this study -both as first-line treatment, in overall treatment and previously prescribed -were fluoroquinolones, ceftriaxone and aminoglycosides (amikacin and gentamycin equally used), which is consistent with reports on empirical treatment in PH [43] . Co-trimoxazole and nitrofurantoin were used only sporadically. To facilitate future studies on antibiotic prescription, a more systematic and standardized way of documentation should be implemented. This does not necessarily only be a part of the patient's medical chart, but could be recorded for the whole ward/clinic together, and contain information as e.g. antibiotic prescription, indication, culture result etc.
A peculiar finding is that in only 54 % of the cases signs and/or symptoms of UTI were noted in the medical chart. It is, however, hard to determine if the other 46 % of the cases actually had ABU, or if information in the charts simply were missing in some cases. To facilitate future studies, a more meticulous and/or standardized recording of key information is recommended.
A majority of the patients were men, contradictory to other studies [32, [36] [37] [38] . Females dominated in the younger ages and males in the older. Patients with some kind of urological condition as primary diagnosis dominated greatly, with surgical conditions and infections in a shared second place. Urological condition was also by far the most common secondary diagnosis. 40 % of the cases had an indwelling urinary catheter when the urine sample were taken, a majority of them being males. Use of indwelling urinary catheter, and surgical-and urological condition were associated with a statistically significant increased likelihood of non-E. coli pathogens. A large number of the cases had one or several risk factors for (complicated) UTI and/or ABR, such as previous instrumentation in the urinary tracts, previous surgery, previous admittance to hospital, previous UTI, and (multiple) previous antibiotics treatments.
Study limitations
The bacterial cultures in this study came from a selected group of patients with an overrepresentation of risk factors for complicated UTI and ABR, and the findings in this study
are not applicable to community-acquired, uncomplicated UTI and UTI-patients in general. It is more likely that the pathogens found and their resistance patterns are representative of the bacteria circulating in the hospital than in the community at large.
Both the log books and the medical charts were hand written. Even though the utmost care have been taken, misinterpretations cannot be ruled out due to the handwritten data and the language barrier. The medical charts were paper sheets stacked within a folder and there is a possibility that sheets were missing. Also, the records are doctor-dependent and absence of information could be interpreted both as lack of recording or e.g. absence of symptoms.
The inclusion criteria of over 100 000 CFU/ml is not used everywhere for UTI, e.g. the Swedish criteria for UTI differ (1, 6) . It was in this study not possible to know if the patient was already on any kind of antibiotic, and whether this could be a contributing factor to the relatively low percentage of positive cultures.
All cases in Part 2 had positive urine cultures, hence there is no control group to compare with. The dropout rate was high, reasons for that could be that the medical charts was misplaced or that the number recorded was incorrectly or unclear. Not all cases had follow-up to evaluate treatment success. This made conclusions about outcome were hard to draw. Also, since only the medical charts from Patan Hospital were available, it is not possible to know if the patients were treated at other health-care facilities, or bought antibiotics over-the-counter.
Information about the antibiotics prescribed was limited to type of antibiotic and first day of prescription, and not duration, dose, or re-prescription. Hence, conclusions about the treatment are somewhat uncertain. Many patients had other infections and conditions requiring antibiotics, and the indications for each antibiotic were most often not possible to determine.
CONCLUSIONS
The findings in this study show an exceptionally high rate of ABR in the surgical department of Patan Hospital, and a low rate of effective empirical antibiotic treatment. To tackle this problem both national and local guidelines are needed to ensure effective (empirical) treatment and to hold back an even further increase in ABR. Empirical treatment should be minimized, and an increased use of nitrofurantoin and amikacin is recommended since these two drugs showed the lowest resistance rates (nitrofurantoin in E. coli, amikacin in all pathogens). Since rates of ABR can vary between settings and over time, a throughout local surveillance of ABR can play an important role in helping clinicians choose the optimal empiric antibiotic treatment and also be an important tool to hamper further increase of ABR.
Further studies are needed in other departments, hospitals and out-patients settings. 
